Skip to content
OpenCapital
Get started

uniQure QURE Lexington Us — PP&E (Net)

Other geography segments

Dutch Sites
$13.15M-32.4%
Other
$185K-19.9%

Similar metrics at other companies

Vaxcyte, Inc. logo
PCVXUNITED STATES — PP&E (Net)
$41.3M+2.0%
Impinj, Inc. logo
PIUS — PP&E (Net)
$13.39M+1.0%
Kodiak Sciences Inc logo
KODUS — PP&E (Net)
$32.1M-9.8%
Payoneer Global Inc. logo
PAYOUS — PP&E (Net)
$2.7M-2.0%
Merit Medical Systems logo
MMSIUS — PP&E (Net)
$300.59M+10.6%
Silicon Laboratories logo
SLABUnited States — PP&E (Net)
$105.86M-0.6%

Other financials

Income statement

See full
Revenue$3.6M+127%
Gross profit$3.3M+144%
Operating income-$45.7M-16.2%
Net income-$53.5M-22.7%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$140.0M-35.6%
Total debt$63.3M-4.3%
Total equity$149.3M+343%
Total assets$778.7M+28.6%

Cash flow

See full
Operating cash flow-$38.2M+13.3%
CapEx$140.0K+11.1%
Free cash flow-$38.4M+13.2%

Valuation

See full
Market cap$3.09B+78.4%
Enterprise value$3.02B+124%
P/S170.9×+85.1×

Profitability

See full
Gross margin90.6%-2.9pp
Operating margin-1,059.7%+380pp
Net margin-1,154.4%+89.3pp
FCF margin-953.7%+169pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.4×-1.5×
Current ratio10.4×-1.6×

Where this comes from

Reported directly by uniQure in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: uniQure’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about uniQure's lexington us — pp&e (net).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is uniQure's lexington us — PP&E (net)?
uniQure (QURE) reported lexington us — PP&E (net) of $461K in Q4 2025.
How has uniQure's lexington us — PP&E (net) changed year-over-year?
uniQure's lexington us — PP&E (net) decreased by 36.8% year-over-year, from $730K to $461K.
What does lexington us — PP&E (net) mean?
Represents the net book value of tangible assets located in the Lexington, US facility after accumulated depreciation and impairment. This metric reflects the company's investment in physical infrastructure required for gene therapy research, development, and manufacturing operations. It serves as a key indicator of the scale and maturity of the company's regional production capabilities.